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Abstract
Background: Pimecrolimus cream 1% is a non-steroid,
selective inflammatory cytokine inhibitor indicated for
atopic dermatitis (AD). Objective: To compare the safety
and efficacy of pimecrolimus cream 1%-based treatment
versus conventional therapy in adults with moderate AD.
Methods: Patients were randomized to receive pimecro-
limus cream 1% (n = 62) or vehicle (n = 68) at the first
signs/symptoms of AD, for 24 weeks as required. A mod-
erately potent topical corticosteroid (prednicarbate
0.25% cream) was allowed in both groups to treat flares.
Results: Corticosteroids were required on fewer days in
the pimecrolimus group, compared with the vehicle
group (9.7 vs. 37.8%, p ! 0.001). Furthermore, 59.7% of
pimecrolimus-treated patients experienced no flares
during the study period, compared with 22.1% of vehi-
cle-treated patients (p ! 0.001). Pimecrolimus cream 1%
was well tolerated throughout the study. Conclusion: For
adults with moderate AD, pimecrolimus cream 1% is
well tolerated, reduces the incidence of flares, reduces/
eliminates corticosteroid use, improves long-term dis-
ease control and enhances the patients’ quality of life.
Copyright © 2004 S. Karger AG, Basel
Introduction
Atopic dermatitis (AD) is a chronic, highly pruritic
skin disorder, which is common in both children and
adults [1]. Historically, the management of AD has been
based on the exclusion of allergens and atopic triggers, the
use of emollients to maintain skin hydration and topical
corticosteroids to treat disease exacerbations [2]. This
paradigm is limited, however, as topical corticosteroids
cannot be used continuously without the risk of side-
effects, of which the most important is skin atrophy [3, 4].
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Corticosteroids are therefore used reactively, with treat-
ment typically initiated only when a severe exacerbation
has developed. Many patients also have negative percep-
tions about the use of topical corticosteroids [5, 6]. Conse-
quently, AD may be inadequately controlled in many
patients.
Pimecrolimus is an anti-inflammatory macrolactam
derivative, specifically developed for the treatment of
inflammatory skin diseases. Pimecrolimus selectively in-
hibits the release of pro-inflammatory mediators from
activated T cells, via the inhibition of calcineurin [7–9].
In higher doses, pimecrolimus can also inhibit the release
of pro-inflammatory cytokines from mast cells [10]. These
actions inhibit the cascade of local immune and inflam-
matory responses central to the pathogenesis of both acute
and chronic AD. However, because the effects of pime-
crolimus are highly specific and cell selective, the drug
does not produce atrophogenic or other steroid-specific
side-effects and can, therefore, be used safely for extended
periods [8, 11, 12]. This safety profile supports a pro-
active management model, in which treatment is initiated
at the first sign of an incipient flare, to prevent progres-
sion to full flare.
To test the new, pimecrolimus-based approach to AD
management in adult patients, a large, randomized, 6-
month study comparing the traditional and novel man-
agement models was conducted [13]. The study demon-
strated that pimecrolimus cream 1% (Elidel®) was a high-
ly effective treatment for AD, substantially reducing the
number of flares and thereby reducing or eliminating the
need for corticosteroids. The first report from this study
included patients with a range of disease severities at
baseline, including both moderate and severe disease [13].
However, pimecrolimus cream 1% is only indicated
in patients with mild to moderate disease; therefore, an
analysis was conducted in which patients with severe AD
were excluded, to provide a clearer indication of the
effects of treatment in the context of the current drug
labelling. Here, we report the results of this 6-month study
in adult patients with moderate AD at baseline.
Patients and Methods
Study Design
This was a randomized, double-blind, parallel-group, multicentre
study conducted at 16 centres in Germany. Patients were recruited
between September 1999 and June 2000. Patients were randomized
1:1 to receive 24 weeks of treatment with either pimecrolimus cream
1% or a corresponding vehicle cream; both groups used emollients
and topical corticosteroids as directed in the protocol and described
in detail below.
Patients were randomly assigned to treatment using computer-
generated lists. To maintain the study blind, the vehicle cream used
in the control group had an identical appearance and odour to pime-
crolimus cream 1%. Blinding was strictly maintained at all times for
all participating patients, healthcare professionals and site-monitor-
ing and data management personnel.
The study was performed according to Good Clinical Practice for
trials on medicinal products in the European Union and the Declara-
tion of Helsinki on medical research in humans. All patients gave
written, informed consent, and the institutional review board and
ethics committees of each participating centre approved the study
protocol.
Patients
All patients had a clinical diagnosis of AD, according to the crite-
ria of Rajka [14]. Patients were required to have AD affecting at least
5% of their total body surface area. The group of patients described
in this report had moderate disease at baseline, defined by an Investi-
gators’ Global Assessment (IGA) score of 3.
Patients were excluded from participation if they had received
systemic corticosteroids, immunosuppressants, cytostatics, psoralen
plus UVA (PUVA) or high-dose UVA within the previous 3 months,
systemic corticosteroids for conditions other than AD within the pre-
vious month, or topical therapies for AD within the previous 2
weeks. Other exclusion criteria were: pregnancy; lactation; women of
child-bearing age not using contraception; severe concurrent allergic
diseases; diseases associated with malignancy or immunosuppres-
sion; the presence of skin conditions that could affect the study treat-
ment; active skin infections requiring treatment with a prohibited
medication; active herpes simplex infection, and the need for potent
topical corticosteroids to control AD.
Study Interventions
Patients applied the study medication (pimecrolimus cream 1%
or corresponding vehicle) twice daily to all affected areas. Treatment
was initiated at the first signs or symptoms of AD (including pruritus
or erythema) and continued until complete clearance. Emollients
were applied to the skin after application of the study medication.
Prednicarbate cream 0.25% (Dermatop®), a moderately potent topi-
cal corticosteroid, was given to patients in both groups if, despite
treatment with the study medication, the itching or pronounced clin-
ical signs of AD (severe erythema, excessive scratch marks or oozing/
crusting) became unacceptable to the patient. Prednicarbate cream
0.25% was used twice daily for a maximum of 7 days, followed by a
reduction to once daily treatment for 7 days or until clearance of the
signs of AD was achieved. After steroid treatment, patients were
required to use the study medication for 7 days to treat any residual
disease and/or prevent disease rebound. Patients were able to use
bland emollients freely throughout the study, but no other active
treatment for AD was permitted, with the exception of the antihista-
mine cetirizine, which could be taken at a constant dose throughout
the study.
Assessments
Patients were assessed at screening (2 weeks to 2 days prior to
randomization), at baseline and weeks 1, 3, 6, 12 and 24. An addi-
tional telephone contact was made during weeks 9 and 18. Un-
scheduled visits were made in the event of flares.
The primary efficacy endpoint was the percentage of days on
which a topical corticosteroid was used. This endpoint provided a
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method of quantifying the ability of the pimecrolimus-based treat-
ment to prevent flares of AD requiring corticosteroid treatment. Sec-
ondary efficacy endpoints included: the number of disease flares; the
time to first flare; IGA score; Eczema Area and Severity Index
(EASI); pruritus rating, and the patients’ self-assessment score.
A flare was defined as a period of at least 3 consecutive days in
which topical corticosteroid application was considered necessary by
the investigator. The pruritus rating was a 4-point score, self-assessed
by patients: 0 = none, 1 = mild, 2 = moderate, 3 = severe. Similarly,
the patients’ self-assessment of disease control was scored on a 4-
point scale: 0 = complete disease control, 1 = good disease control,
2 = limited disease control, 3 = uncontrolled disease.
Prior to the study, all investigators were required to undergo
training in IGA and EASI assessments. The IGA is a static (i.e. no
reference to baseline state), 6-point measure of disease severity based
on an overall assessment of skin lesions. An IGA score of 0 (clear)
corresponds to no inflammatory signs of AD, 1 (almost clear) to just
perceptible erythema and just perceptible papulation/infiltration, 2
(mild) to mild erythema and mild papulation/infiltration, 3 (moder-
ate) to moderate erythema and moderate papulation/infiltration, 4
(severe) to severe disease with severe erythema and severe papula-
tion/infiltration and 5 (very severe disease) to severe erythema and
severe papulation/infiltration with oozing/crusting. An IGA score of
0 (clear) to 2 (mild disease) at the study endpoint was categorized as
treatment success.
The EASI is a composite score that assesses the severity of erythe-
ma, infiltration/papulation, excoriation and lichenification in the 4
body regions (head/neck, trunk, upper limbs and lower limbs) as well
as the surface area involvement. The results from different body
regions are adjusted by age and combined to yield a score of 0–72
[15].
The impact of treatment on quality of life was assessed using two
instruments: the Quality of Life Index for Atopic Dermatitis
(QoLIAD) and the Dermatology Life Quality Index (DLQI). The
QoLIAD is a 25-item questionnaire, with each question requiring an
answer of either yes (score = 1) or no (score = 0). The QoLIAD is
expressed as a percentage of the maximum possible score of 25; the
higher the score, the greater the impairment of quality of life [16].
The DLQI is a 10-part questionnaire relating to symptoms and per-
ception of disease, daily activities, work or school, personal relation-
ships, leisure and consequences of treatment, with each question
scored 0–3. The score is expressed as a percentage of the maximum
possible score of 30 and, similarly to the QoLIAD, the higher the
score, the greater the impairment of quality of life [17].
Adverse events were recorded throughout the study. Physical
examination, standard haematology and blood chemistry tests were
performed at regularly scheduled intervals. Patients also completed
diaries, in which they recorded medication use, changes in medical
condition and pruritus score from 0 (none) to 4 (very severe).
Statistical Analysis
Only patients with an IGA score of 3 (moderate disease) at base-
line were included in the analysis. Statistical analyses were per-
formed on the intention-to-treat population, defined as all random-
ized patients to whom the study medication was dispensed. The last
observation carried forward method was used to impute data for all
missing endpoints. The primary efficacy endpoint was the percent-
age of days on which corticosteroid was administered, i.e. the num-
ber of days on which steroid was taken, expressed as a percentage of
the total number of days from week 0 to week 24. Data from patients
who withdrew from the study due to lack of efficacy or adverse events
were analysed as though the patients had used topical corticosteroids
for the remainder of the study. The 2 treatment groups were compared
using the Wilcoxon rank sum test at a significance level of 5%.
In secondary efficacy analyses, tests were used in an exploratory
fashion. Treatment groups were compared using analysis of covari-
ance (ANCOVA), the Wilcoxon rank sum test, Fisher’s exact test or
logistic regression, as appropriate. Time to first flare data were ana-
lysed using survival analytical methods (log rank test). The effect of
baseline variables on time to first flare was investigated by fitting a
Cox proportional hazards model, including the following factors:
centre, baseline IGA, baseline EASI, age category and treatment
group. The EASI was analysed using ANCOVA.
Quality of life was assessed at baseline, week 6 and week 24, with
summary statistics calculated at each of these time points for each
treatment group. Safety analysis was descriptive, with group compar-
isons for adverse events made using Fisher’s exact test.
Differences between groups in laboratory parameters were com-
pared using the Wilcoxon rank sum test.
Results
Patients
Of the 192 patients randomized for treatment, 130 had
moderate disease at baseline, as defined by an IGA score
of 3. A total of 62 patients with moderate disease at base-
line were randomized to pimecrolimus cream 1%-based
treatment, and 68 were randomized to conventional treat-
ment (control group). A flow diagram of patient randomi-
zation and treatment outcomes is shown in figure 1, and
the patients’ demographics and clinical characteristics are
summarized in table 1.
Table 1. Baseline demographics and clinical characteristics
Pimecrolimus
cream 1% (n = 62)
Control
(n = 68)
Age, years
Mean B SD
Median
Range
29.2B9.7
27.0
18U65
31.4B10.0
29.0
18U66
Gender, n
Male
Female
25 (40.3%)
37 (59.7%)
25 (36.8%)
43 (63.2%)
Total body surface area affected, %
Mean B SD
Range
13.9B5.8
6.0U30.0
12.7B5.8
5.0U27.0
EASI
Mean B SD
Range
9.3B3.9
2.0U20.9
8.6B4.0
2.6U19.4
SD = Standard deviation.
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Fig. 1. Flow diagram of patient randomization and
treatment outcomes. ITT = Intention to treat.
There were no significant demographic or clinical dif-
ferences between the 2 groups at baseline, and the age dis-
tributions and gender ratios were similar. All patients
except 2 (both in the control group) were Caucasian. The
mean body surface area affected by AD at baseline was
approximately 14% in the pimecrolimus group and 13%
in the control group. The median EASI was 8.8 for both
the pimecrolimus group and control group, which is con-
sistent with the classification of these patients by the IGA
score as having moderate disease.
In total, 38.2% of patients in the control group discon-
tinued early, compared with only 9.7% of patients in the
pimecrolimus group (p ! 0.01). The principal reason for
this difference was the greater number of patients in the
control group who discontinued treatment due to an un-
satisfactory therapeutic effect (27.9 vs. 8.1%, respectively;
p = 0.01).
Efficacy
Treatment with pimecrolimus cream 1% resulted in a
significant reduction in the percentage of days on which
patients used topical corticosteroids. In total, 37 patients
(59.7%) in the pimecrolimus group did not use corticoste-
roids at all during the study, compared with 17 patients
(25.0%) in the control group. During the 6 months of the
study, patients in the pimecrolimus group used corticoste-
roids for a mean of 9.7% of study days, compared with
37.8% of study days in the control group (p ! 0.001).
Consistent with these findings, the number of flares was
significantly lower in the pimecrolimus group (table 2),
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Fig. 2. Median percentage change in EASI over 24 weeks. *** p !
0.0001, ** p ! 0.001, * p ! 0.01 (pimecrolimus vs. control).
Fig. 3. Rapid relief of pruritus. *** p ! 0.0001, ** p ! 0.001, * p !
0.01 (pimecrolimus vs. control). Pimecrolimus n = 51, control n = 60;
pruritus relief defined as pruritus score of 0 (absent) or 1 (mild).
compared with the control group. In total, 37 patients
(59.7%) who were treated with pimecrolimus cream 1%
had no flares during the course of the study, compared
with 15 patients (22.1%) in the control group (p ! 0.001).
The mean number of flares among patients in the pime-
crolimus group was 1.0 B 1.5, compared with 2.3 B 2.5
in the control group (p ! 0.001).
Treatment with pimecrolimus cream 1% produced a
rapid improvement in the signs and symptoms of AD,
which was sustained throughout the course of the study.
The median EASI for the pimecrolimus group decreased
during the course of the study from 8.8 to 2.1, a reduction
of 71.1%; however, it changed far less in the control
group, decreasing only from 8.8 to 5.2, a reduction of
11.6% (p ! 0.0001) (fig. 2). Treatment success, defined as
an IGA score of 0–2, was achieved in 50 patients (80.6%)
in the pimecrolimus group, compared with 25 patients
(36.8%) in the control group (p ! 0.001).
Pruritus improved rapidly following treatment with
pimecrolimus cream 1%. On the second day of treatment,
the percentage of patients with a pruritus score of 0 (none)
or 1 (mild) was already significantly higher in the pime-
crolimus group than in the control group (p ! 0.01) (fig. 3).
By week 24, a total of 43 patients (69.3%) in the pimecro-
limus group reported no or mild pruritus, compared with
24 patients (35.3%) in the control group (p ! 0.001).
Results of the patients’ self-assessment showed that 45
patients (72.6%) in the pimecrolimus group and 26 pa-
tients (38.2%) in the control group considered disease con-
trol to be good or complete by week 24 (p ! 0.001).
Table 2. Number of flares over 24 weeks (%)
Number
of flares
Not including
discontinuations
pimecrolimus
cream 1%
(n = 56)
control
(n = 43)
Including
discontinuations
pimecrolimus
cream 1%
(n = 62)
control
(n = 68)
0 66.1 35.7 59.7 22.1
1 10.7 16.7 9.7 10.3
2 3.6 14.3 3.2 8.8
63 19.6 33.3 27.4 58.8
Quality of Life
Quality of life improved rapidly and substantially in
the patients treated with pimecrolimus cream 1%. By the
first post-baseline assessment at week 6, quality of life – as
assessed by mean QoLIAD score – had improved by
25.5% in the pimecrolimus group, compared with only
2.1% in the control group (p ! 0.001). By week 24 (fig. 4),
the mean QoLIAD score had improved by 34.9% in the
pimecrolimus group, compared with 10.5% in the control
group (p = 0.002).
Similarly, the mean DLQI score at week 6 had im-
proved by 25.3% in the pimecrolimus group, compared
with a deterioration from baseline of 8.8% in the control
group (p ! 0.001). By week 24 (fig. 4), the mean DLQI
score had improved by 22.9% in the pimecrolimus group,
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Fig. 4. Improvement in quality of life at 24 weeks. * p ! 0.01 (pime-
crolimus vs. control).
Table 3. Number of patients with adverse events
Pimecrolimus
cream 1%
(n = 62)
Control
(n = 68)
Any adverse event
Serious adverse events
Skin infections
Herpes simplex infections
Eczema herpeticum
Herpes simplex otitis externa
Folliculitis
Furuncle
Erysipelas
Stye
Tinea pedis
Skin infection NOS
46 (74.2)
1 (1.6)
13 (21.0)
7 (11.3)
0 (0.0)
0 (0.0)
0 (0.0)
2 (3.2)
1 (1.6)
0 (0.0)
0 (0.0)
1 (1.0)
51 (75.0)
2 (2.9)
8 (11.8)
3 (4.4)
1 (1.5)
1 (1.5)
1 (1.5)
1 (1.5)
0 (0.0)
2 (2.9)
1 (1.5)
0 (0.0)
Withdrawals due to adverse events 0 (0.0) 5 (7.4)
Drug-related adverse events
Application site reactions
(burning/erythema/pain/pruritus)
Infections and infestations
Herpes simplex infections
Eczema herpeticum
Burning sensation
Unspecified lesions (acne/dermatitis/
erythema/oedema/pruritus)
14 (22.6)
9 (14.5)
2 (3.2)
0 (0.0)
2 (3.2)
1 (1.6)
16 (23.1)
6 (8.8)
1 (1.5)
1 (1.5)
2 (2.9)
10 (14.7)
Results are numbers, with percentages in parentheses. NOS = Not
otherwise specified.
compared with just 0.9% in the control group (p =
0.007).
Safety
Pimecrolimus cream 1% was well tolerated throughout
the study. No patients in the pimecrolimus group, and
only 3 patients in the control group, withdrew from the
study due to adverse events. The only serious adverse
event reported in the pimecrolimus group was a case of
erysipelas that was considered to be unrelated to the study
medication.
The overall incidence of drug-related adverse events in
the pimecrolimus and control groups was similar (22.6
and 23.1%, respectively) (table 3). Local application site
reactions were the most common treatment-related ad-
verse events. In total, 9 patients (14.5%) in the pimecroli-
mus group and 6 (8.8%) in the control group had a local
application site reaction. Local tolerability was good, and
application site burning was generally mild and transient,
resolving within 1–7 days.
A total of 13 patients (21.0%) in the pimecrolimus
group and 8 (11.8%) in the control group experienced a
skin infection. Bacterial and fungal infections occurred at
similar frequencies in both groups, but certain viral infec-
tions were more common in the pimecrolimus group. Spe-
cifically, 7 patients (11.3%) in the pimecrolimus group,
compared with 3 (4.4%) in the control group, had an epi-
sode of herpes simplex infection. However, 4 of these 7
cases in the pimecrolimus group were herpes labialis (i.e.
involving an area not treated by the study medication),
compared with only 1 of the 3 cases in the control group.
In total, 2 cases of herpes simplex in the pimecrolimus
group and 1 in the control group were considered to be
related to the study medication. No patient in the pime-
crolimus group developed eczema herpeticum or herpes
simplex otitis externa, compared with 1 case each in the
control group.
No clinically relevant laboratory abnormalities were
observed during the course of the study.
Discussion
This 6-month study in adult patients with moderate
AD has demonstrated that the use of pimecrolimus cream
1%, administered at the first signs or symptoms of an
inflammatory exacerbation, prevents progression to flare
and significantly reduces or eliminates the need for topi-
cal corticosteroids. Furthermore, long-term disease con-
trol is more effective with pimecrolimus cream 1%, with
Long-Term Safety and Efficacy of
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fewer flares, a greater improvement in the signs and
symptoms of AD and enhanced patient quality of life,
compared with conventional therapy.
Approximately 60% of pimecrolimus-treated patients
did not use topical corticosteroids at all during the entire 6
months and did not experience a single flare during this
period. On average, the patients treated with pimecroli-
mus cream 1% used topical corticosteroids on !10% of
study days. The effects of treatment with pimecrolimus
cream 1% on AD symptoms were rapid and sustained,
with more than 50% of patients reporting either no or
mild pruritus within 1 week of treatment initiation, and a
reduction of 170% in the median EASI score by week 24.
Treatment success, defined as an IGA score of 0 (clear) to
2 (mild disease), was achieved in more than 80% of the
patients treated with pimecrolimus cream 1%. These clin-
ical benefits were associated with significant improve-
ments in quality of life, as determined by two different
assessment instruments, the QoLIAD and the DLQI.
Pimecrolimus cream 1% was well tolerated and had a
good safety profile throughout the study. Consistent with
previous studies with pimecrolimus cream 1%, the most
common adverse event was application site burning,
which was reported by 9 (14.5%) of patients. Application
site burning is generally a mild and transient reaction that
resolves within a few days. No cases of application site
burning led to withdrawal from the study.
It was notable that 7 cases of herpes simplex infection
were observed in the pimecrolimus group during the
course of the study, compared with 3 cases in the control
group. This difference was not statistically significant and
does not take into account the longer average time spent
on the study by patients in the pimecrolimus group. Fur-
thermore, 4 of these viral infections in the pimecrolimus
group were herpes labialis infections, compared with only
1 in the control group. These infections occurred on the
lips, which were unaffected by AD and untreated by the
study medication; the imbalance in the incidence of
herpes simplex is therefore most likely to have been a
chance occurrence.
The results of this investigation are similar to those
described in a previous report, which also included data
for patients with severe disease at baseline [13]. The
present report focuses specifically on moderate AD and
demonstrates that pimecrolimus cream 1% is clinically
highly beneficial in this more narrowly defined group.
The results add to a growing data set from several clinical
trials, showing that pimecrolimus cream 1% is consistent-
ly effective across a range of disease severities and has a
good safety profile, demonstrating no clinically relevant
systemic side-effects in 15,000 patients studied, from
infants to adults [13, 18–21].
In conclusion, this study demonstrates that in adult
patients with moderate AD, long-term management with
pimecrolimus cream 1% prevents flares in the majority of
patients and even eliminates the reliance on topical ste-
roids, improves the signs and symptoms of disease and
enhances quality of life. The benefits of treatment were
sustained over 6 months. These findings indicate that
management with pimecrolimus cream 1% has the poten-
tial to significantly improve the long-term control of AD
in patients with moderate disease.
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